UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
]
FORM 10-Q
QUARTERLY REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the Third quarter ended Commission file number
June 30, 2005 33-27042-NY
- --------------------------- ----------------------
BARRINGTON SCIENCES CORPORATION
------------------------------------------------
(Formerly known as: Financial Express Corporation)
(Exact name of registrant as specified in its charter)
Nevada 93-0996537
------ ----------
(State of Incorporation) (I.R.S. Employer
Identification No.)
1107 Bennet Drive
Port Coquitlam, British Columbia, Canada V3C 6H2
- ---------------------------------------- -------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number: (604) 868-7400
Securities registered pursuant to Section 12(b) of the Act:
NONE NONE
(Title of Each Class) (Name of Each Exchange
on which Registered)
Securities registered pursuant to Section 12 (g) of the Act:
Common
(Title of Class)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the registrant
was required to file such reports) and (2) has been subject to such filing
requirements for the past 90 days.
(1) Yes X No (2) Yes X No
----- ----- ----- -----
Indicate by check mark whether the registrant is a large accelerated filer, an
accelerated filer, or a non-accelerated filer. See definition of "accelerated
filer and large accelerated filer" in Rule 12b-2 of the Exchange Act. (Check
one):
Large accelerated filer Accelerated filer Non-accelerated filer X
--- --- ---
Indicate by check mark whether the registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act). Yes [ X ] No [ ]
The number of shares of the Common Stock of the registrant outstanding as of
June 30, 2005 was 24,379,477. The aggregate common stock held by non-affiliates
on June 30, 2005 was 10,393,536.
BARRINGTON SCIENCES INTERNATIONAL CORPORATION
(A development stage enterprise)
-----------------------------
INDEX
Page No.
--------
Part I. Financial Information
- ------- ---------------------
Item 1. Financial Statements
- ------ ---------------------
Independent Registered Auditors Report 4
Balance Sheet - at June 30, 2005 5
Statements of Operations - for the
quarters ended June 30, 2005 and June 30, 2004 6
Statement of Cash Flows - for the
Quarters ended June 30, 2005 and 2004 8
Notes to Financial Statements 9
Item 2. Management's Discussion and Analysis
of Financial Condition and Results of Operations 10
Item 3. Quantitative and Qualitative Disclosures About Market Risk 10
Item 4. Controls and Procedures 10
Part II. Other Information
------- -----------------
Item 1. Submission of Matters to a Vote of Security Holders 10
Item 2. Changes in Securities 10
Item 3. Defaults Upon Senior Securities 10
Item 4. Submission of Matters to a Vote of Security Holders 11
Item 5. Other Information 11
Item 6. Exhibits and Reports on Form 8-K 11
MOORE & ASSOCIATES, CHARTERED
ACCOUNTANTS AND ADVISORS
------------------------
PCAOB REGISTERED
Report of Independent Registered Public Accounting Firm
-------------------------------------------------------
To the Board of Directors
Barrington Sciences Corporation
We have reviewed the accompanying balance sheet of Barrington Sciences
Corporation as of June 30, 2005, and the related statements of operations,
retained earnings, and cash flows for the nine months then ended, in accordance
with the standards of the Public Company Accounting Oversight Board (United
States). All information included in these financial statements is the
representation of the management of Barrington Sciences Corporation
A review consists principally of inquiries of company personnel and analytical
procedures applied to financial data. It is substantially less in scope than an
audit in accordance with generally accepted auditing standards, the objective of
which is the expression of an opinion regarding the financial statements taken
as a whole. Accordingly, we do not express such an opinion.
Based on our review, we are not aware of any material modifications that should
be made to the financial statements in order for them to be in conformity with
generally accepted accounting principles.
The accompanying financial statements have been prepared assuming that the
company will continue as a going concern. The financial statements do not
include any adjustments that might result from any uncertainty.
/s/ Moore & Associates, Chartered
Moore & Associates, Chartered
Las Vegas, Nevada
April 18, 2007
2675 S. JONES BLVD. SUITE 109, LAS VEGAS, NEVADA 89146
(702) 253-7511 Fax: (702)253-7501
-4-
BARRINGTON SCIENCES CORPORATION
(A development stage enterprise)
Balance Sheet
As at June 30, 2005
Current assets:
Cash 68,834
Prepaid and other current assets --
----------
Total current assets 68,834
----------
Investment in Joint Venture 335,759
----------
Total assets 404,593
----------
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable and accrued liabilities 116,629
----------
Payable to Related parties 375,647
----------
Total Liabilities 492,276
----------
Stockholders' equity:
Common stock $.001 par value;
100,000,000 authorized; 24,379,977 issued
and outstanding 24,379
Additional paid in Capital 4,271,654
----------
4,296,033
Losses accumulated during the
development stage (4,383,716)
Total stockholders' equity (87,683)
----------
Total liabilities and stockholders' equity 404,593
----------
See accompanying notes
Note
The Financial statements have been prepared by Management
-5-
BARRINGTON SCIENCES CORPORATION
(A development stage enterprise)
STATEMENTS OF OPERATIONS
For the six months ended June 30, 2005 and 2004
Period From
Oct 2004 to October 2003 Inception Inception To
June 2005 June 2004 To Sept 30/04 June 30, 2005
--------- --------- ------------- -------------
Sales -- -- $ 10,736 $ 10,736
Cost of sales 17,437 17,437
Selling, general and administrative 11,416 275,573 2,368,318 2,379,734
Write-down of goodwill 910,249 910,249
Write-down of intangibles and inventory 812,546 812,546
Write-down of other assets -- -- 233,794 233,794
------------ ------------ ------------ ------------
11,416 275,573 4,342,344 4,353,760
(Loss) from operations 11,416 275,573 4,331,608 4,343,024
------------ ------------ ------------ ------------
Other income (expense)
Interest expense -- -- (40,692) (40,692)
------------ ------------ ------------ ------------
Net (loss) $ 11,416 $ 275,573 $ 4,372,300 $ 4,383,716
============ ============ ============ ============
Per share information:
Basic and diluted (loss)
per common share $ 0.00 $ 0.01 $ 0.18 $ (0.18)
============ ============ ============ ============
Weighted average shares outstanding 24,301,063 24,199,342 24,281,477 24,301,063
============ ============ ============ ============
-6-
BARRINGTON SCIENCES CORPORATION
(A development stage enterprise)
STATEMENTS OF OPERATIONS
For the three months ended June 30, 2005 and 2004
Quarter Quarter
June 2005 June 2004
--------- ---------
Sales $ -- $ --
Selling, general and administrative 58 8,126
Write-down of other assets -- --
----------- -----------
(Loss) from operations 58 8,126
Other income (expense)
Interest expense -- --
----------- -----------
Net (loss) $ 58 $ 8,126
----------- -----------
Per share information:
Basic and diluted (loss)
per common share $ 0.0000 $ 0.000
----------- -----------
Weighted average shares outstanding 24,301,063 24,199,342
----------- -----------
See accompanying notes
-7-
BARRINGTON SCIENCES CORPORATION
(A development stage enterprise)
STATEMENTS OF CASH FLOWS
For the six months ended June 30, 2005 and 2004
(Unaudited)
Inception
30-Jun-05 30-Jun-04 to date
-----------------------------------------------------
OPERATING ACTIVITIES
Net Loss 11,416) (275,573) (4,383,716)
Items not affecting cash:
Depreciation and amortization 0 1,786 0
Changes in non-cash working capital:
Accounts receivable 0 3,682
Subscriptions Recievable
Prepaids and other current assets 0 (1,000) 0
Bank Overdraft 0 (123,196)
Accounts payable and accrued liabilities 11,309) 11,916 116,629
Inventory 0
Payable Related Parties /other 20,617) 213,357 375,647
-----------------------------------------------------
Cash flow used by operating activities 43,342) (169,028) (3,891,440)
-----------------------------------------------------
INVESTING ACTIVITIES
Purchase of capital assets/Sale 0 112,068 0
Additions to Intangible Assets
Deposit on Acquisitions
Investment in Joint Venture (335,759)
-----------------------------------------------------
Cash flow from investing activities 0 112,068 (335,759)
-----------------------------------------------------
FINANCING ACTIVITIES
Increase (decrease) in short term debt
Issuance of common shares 98,500 56,960 4,296,033
Foreign Currency Adjustment
-----------------------------------------------------
Cash flow from financing activities 98,500 56,960 3,960,274
-----------------------------------------------------
INCREASE IN CASH FLOW 55,158 0 68,834
CASH - Beginning of period 13,676 0 0
-----------------------------------------------------
CASH - End of period 68,834 0 68,834
-----------------------------------------------------
-8-
BARRINGTON SCIENCES CORPORATION
NOTES TO FINANCIAL STATEMENTS
June 30, 2005
1. Basis of presentation
- ------------------------
General
-------
On December 30, 2002, Barrington Sciences International Corporation
("BSIC") completed the sale of its assets to Financial Express Corporation
("FEC"), a public Nevada corporation, in a reverse merger. The accompanying
financial statements include the accounts of Barrington Sciences International
Corporation and its wholly owned subsidiaries, and the activity of FEC from the
date of acquisition. In connection with the transaction, the fiscal year of
BSIC, September 30, was adopted.
The accompanying condensed unaudited financial statements have been
prepared in accordance with generally accepted accounting principles for interim
financial information and with the instructions to form 10-Q. Accordingly, they
do not include all of the information and footnotes required by generally
accepted accounting principles for complete financial statements. In the opinion
of management, all adjustments (consisting of normal recurring adjustments)
considered necessary for a fair presentation have been included.
Stockholders' equity
--------------------
Basic (loss) per share was computed using the weighted average number of
common shares outstanding.
-9-
Item 2. Management's Discussion and Analysis of Financial Condition and
Plan of Operations
(a) Plan of Operation
The Company has generated no revenues from its operations and has been
a development stage enterprise since inception.
The company has discontinued the joint venture in China and is in the
process of bringing all filings current in order to attract an operation to
vend into it.
(b) Liquidity and capital resources
Management has abandoned efforts to raise equity for future
development of its operations Instead it is seeking a viable alternative to
vend into the company
(c) Comparison of 2005 and 2004 for the third quarter.
Operating costs decreased as the company curtailed operations due to
cash constraints. Total operating costs reduced from $8,126 in 2004 to $58
in 2005. The costs consisted of: Travel costs (2004), some office costs.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
None. The Company does not hold any material market risk sensitive
instruments.
Item 4. Controls and Procedures
At the present time the company does not have a controls and
procedures system in place.
PART II Other Information.
- ------- ------------------
Item 1. Legal Proceedings.
None
Item 2. Changes in Securities
None this quarter
Item 3. Defaults Upon Senior Securities
(Not applicable)
-10-
Item 4. Submission of Matters to a Vote of Security Holders
None
Item 5. Other Information
(Not applicable)
Item 6. Exhibits and Reports on Form 8-K
(a) Exhibits
None this quarter
(b) Reports on Form 8-K
None
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
BARRINGTON SCIENCES CORPORATION
Date: May 1, 2007
By: /s/ Lorne Broten
----------------
Lorne Broten
CFO and Director (Principal Financial Officer)
-11-
Supplemental Information to be Furnished With Reports Filed Pursuant to Section
15(d) of the Act by Registrants Which Have Not Registered Securities Pursuant to
Section 12 of the Act
No annual report or proxy material has been sent to security holders of the
Company. The Company does not anticipate sending out a separate annual report or
proxy material to its security holders subsequent to the filing of the annual
report. In the event that the Company determines that it will send out either a
separate annual report or any proxy materials, the Company will furnish copies
of such material to the Securities and Exchange Commission when it is sent to
security holders.